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Systematic review and meta-analysis of linezolid versus daptomycin for 
treatment of vancomycin-resistant enterococcal bacteremia 
Abstract 
Limited therapeutic options exist for the treatment of vancomycin-resistant Enterococcus (VRE) 
bacteraemia; the most commonly used are daptomycin and linezolid. We attempted a systematic review 
and meta-analysis on the comparative efficacy of those two agents. Studies comparing daptomycin to 
linezolid treatment for VRE bacteraemia, published until August 2012 were identified from MEDLINE, 
EMBASE, CENTRAL, ISI Web of Science and SCOPUS databases. All comparative studies on patients 
older than 18 years old that provided mortality data were considered eligible for this systematic review 
and meta-analysis. Τhe primary outcome of the meta-analysis was 30-day all-cause mortality. Ten 
retrospective studies including 967 patients were identified. Patients treated with daptomycin had 
significantly higher 30-day all-cause mortality (OR: 1.61, 95% CI: 1.08 to 2.40) and infection-related 
mortality (OR: 3.61, 95% CI: 1.42 to 9.20) rates compared to those treated with linezolid. When data from 
all ten studies were combined overall mortality was also significantly increased among patients treated 
with daptomycin (OR: 1.41, 95% CI: 1.06 to 1.89). These findings were confirmed when odds ratios 
adjusted for potential confounders were pooled. Relapse rates among patients treated with daptomycin 
were also higher (OR: 2.51, 95% CI: 0.94 to 6.72), although this difference did not reach statistical 
significance. Adverse event rates were not significantly different between the two groups. 
Notwithstanding the absence of randomized prospective data, available evidence suggests that mortality 
rates may be higher with daptomycin compared with linezolid among patients treated for VRE 
bacteraemia. 
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Limited therapeutic options exist for the treatment of vancomycin-resistant 24 
Enterococcus (VRE) bacteraemia; the most commonly used are daptomycin and 25 
linezolid. We attempted a systematic review and meta-analysis on the comparative 26 
efficacy of those two agents. Studies comparing daptomycin to linezolid treatment for 27 
VRE bacteraemia, published until August 2012 were identified from MEDLINE, 28 
EMBASE, CENTRAL, ISI Web of Science and SCOPUS databases. All comparative 29 
studies on patients older than 18 years old that provided mortality data were 30 
considered eligible for this systematic review and meta-analysis. ȉhe primary 31 
outcome of the meta-analysis was 30-day all-cause mortality. Ten retrospective 32 
studies including 967 patients were identified. Patients treated with daptomycin had 33 
significantly higher 30-day all-cause mortality (OR: 1.61, 95% CI: 1.08 to 2.40) and 34 
infection-related mortality (OR: 3.61, 95% CI: 1.42 to 9.20) rates compared to those 35 
treated with linezolid. When data from all ten studies were combined overall mortality 36 
was also significantly increased among patients treated with daptomycin (OR: 1.41, 37 
95% CI: 1.06 to 1.89). These findings were confirmed when odds ratios adjusted for 38 
potential confounders were pooled. Relapse rates among patients treated with 39 
daptomycin were also higher (OR: 2.51, 95% CI: 0.94 to 6.72), although this 40 
difference did not reach statistical significance. Adverse event rates were not 41 
significantly different between the two groups. Notwithstanding the absence of 42 
randomized prospective data, available evidence suggests that mortality rates may be 43 





Enterococci are the third most common cause of healthcare-associated bloodstream 48 
infections (BSIs) (1). Vancomycin is the first-line treatment of BSIs caused by 49 
ampicillin-resistant enterococci; however vancomycin-resistant enterococci (VRE) 50 
nowadays account for approximately one third of the enterococcal healthcare-51 
associated infections in the United States (2) and more than 20% in some European 52 
countries, respectively. (European Centre for Disease Prevention and Control. 53 
Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European 54 
Antimicrobial Resistance Surveillance Network (EARS-Net). 55 
Stockholm:ECDC;2010.http://ecdc.europa.eu/en/publications/Publications/1011_SUR56 
_annual_EARS_Net_2009.pdf). Mortality rates in patients with VRE BSIs range 57 
between 20 and 46% (3-5). Patients with BSI due to VRE are 2.5 times more likely to 58 
die than patients with BSI due to vancomycin-susceptible strains (6).
 
59 
Treatment of VRE BSIs is particularly challenging. Those strains are usually resistant 60 
to ampicillin (7) and therapeutic options include linezolid, daptomycin, quinupristin-61 
dalfopristin, tigecycline, teicoplanin and telavancin (for which limited clinical data are 62 
available). Teicoplanin is not available in the USA and could only be used for some 63 
VRE infections (i.e. strains with the VanB -vancomycin-resistant, teicoplanin-64 
susceptible- phenotype and the rare E. gallinarum and E. casseliflavus). Tigecycline 65 
does not achieve high serum concentrations and has not been approved for treatment 66 
of bacteremias (8). Use of quinupristin-dalfopristin (effective only against E. faecium) 67 
is limited by the need of central venous access for administration, frequent side effects 68 
and drug interactions (9). 69 
Clinical experience and data for the treatment of VRE BSIs are mainly available for 70 
linezolid and daptomycin. Linezolid has been approved by the United States Food and 71 
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Drug Administration (FDA) for the treatment of vancomycin-resistant E. faecium 72 
infections, including those with concurrent bacteraemia. Although daptomycin is not 73 
FDA-approved for the treatment of VRE bacteraemia, its rapid bactericidal activity 74 
(10, 11) offers an off-label alternative (12, 13). According to the relevant clinical 75 
practice guidelines of the Infectious Diseases Society of America, linezolid or 76 
daptomycin are recommended for the treatment of catheter-related BSIs caused by 77 
ampicillin- and vancomycin-resistant enterococci (14). Limited data exist on the 78 
comparative efficacy of daptomycin versus linezolid for enterococcal bacteremias (4, 79 
5). Herein, we summarize the available evidence and provide an estimate on the 80 
clinical effectiveness of linezolid versus daptomycin for the treatment of VRE 81 
bacteremia, by using meta-analytic methodology.  82 
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Materials and Methods 83 
Search Strategy 84 
A computerized literature search in MEDLINE, EMBASE, CENTRAL, ISI Web of 85 
Science and SCOPUS electronic databases covering the period until 31
st
 August 2012 86 
was performed independently by two of the authors (EPB, CAV). The strategy 87 
employed for this study is presented in detail in the supplemental material.  88 
Selection of studies 89 
In order for the studies to be eligible for this systematic review, the following 90 
inclusion criteria were established prior to literature search: a) studies should compare 91 
the outcomes of treatment between daptomycin and linezolid for VRE bacteraemia in 92 
two groups of patients; b) patients should be older than 18 years; and c) the study 93 
should provide data on patient mortality outcomes. 94 
All studies identified to address the research question were initially considered for the 95 
present systematic review, regardless of the direction of study (retrospective or 96 
prospective) and their sample size. Case reports and case series of patients treated 97 
with either one of the two agents were not included. 98 
Studies identified 99 
The electronic search resulted in the retrieval of 2365 publications (see Fig. S1 in the 100 
supplemental material). Their titles were screened to exclude irrelevant studies, 101 
resulting in 46 potentially eligible studies. The search of the meetings’ abstracts 102 
resulted in the retrieval of eight additional studies. Out of the total 54 studies, 39 were 103 
excluded after examining their abstracts (eight retrospective, non-comparative studies, 104 
26 reviews and opinion papers, five irrelevant studies), while four further studies 105 
published in meetings proceedings were excluded as they provided data already 106 
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included in the identified published full texts (overlapping publications) (15-18). 107 
Eventually, eleven studies were considered for further evaluation. One study was 108 
excluded at this stage, since daptomycin was not included in the comparator agents 109 
(19).  110 
The full reference lists of the studies whose full text was examined were hand-111 
searched, which did not result in the identification of any additional studies, neither 112 
did the search of the clinical trials registries. Eventually, ten studies comparing the 113 
efficacy of daptomycin and linezolid for the treatment of VRE bacteraemia were 114 
included in this systematic review and meta-analysis (4, 5, 20-27).  115 
Data extraction  116 
The methodology that was followed for extracting the data is described in the 117 
supplemental material. 118 
Outcomes 119 
The primary outcome examined in the meta-analysis was mortality, expressed as 30-120 
day all-cause mortality (defined as death from any reason within 30 days from the 121 
first culture positive for VRE). ǿnfection-related mortality (defined as death attributed 122 
to VRE bacteraemia) and in-hospital mortality (defined as death from any reason 123 
during hospital stay) were also evaluated. Since mortality end-points were different 124 
across studies,  a composite outcome -defined as overall mortality- was also 125 
calculated, by including any relevant comparison on mortality rates between 126 
daptomycin and linezolid, irrespective of the definition used (i.e all-cause; infection-127 
related; in-hospital; 30-day; etc.). When some data on the outcomes of interest 128 
were not provided in the full-text papers or abstracts, the authors were contacted for 129 
further information. 130 
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Secondary outcome measures included: a) clinical cure (defined as a resolution of 131 
signs and/or symptoms of infection after treatment for VRE was discontinued); b) 132 
microbiological cure (the last blood culture, drawn after initiation of VRE treatment, 133 
being negative); c) recurrence of VRE bacteraemia (a post-treatment blood culture 134 
positive for VRE, following at least one negative blood culture); and d) adverse 135 
events (defined as the development of an adverse event proven or suspected to be 136 
related to the agent used for VRE treatment or to the route of administration). 137 
Quantitative data synthesis 138 





Systematic review 143 
The ten studies identified as fulfilling the inclusion criteria for the systematic review 144 
included 967 patients in total. The characteristics of those studies are listed in the 145 
supplemental material, Tables S2-S4.  146 
All studies were published between 2005 and 2012 and were of retrospective cohort 147 
nature. Two were multicenter studies (21, 27), 7 reported the experience of single 148 
centers, whereas in one this information was not provided (26). The primary outcome 149 
measure was microbiological cure in two studies (20, 27), 30-day all-cause mortality 150 
in one study (4), clinical and microbiological cure in one study (5), while in five 151 
studies the primary outcome among those examined was not stated.  152 
The sample size of the included studies ranged from 31 to 201 patients (median 82). 153 
With two exceptions (25, 26), the studies included mixed populations with varying 154 
percentages of immunocompromised and non-immunocompromised patients (see 155 
Table S2 in the supplemental material). 156 
Definitions of VRE BSIs differed slightly across studies. The Centers for Disease 157 
Control (CDC) definition for enterococcal bacteraemia was used in four studies (4, 158 
20, 25, 27). Two or more positive blood cultures or one positive with an identifiable 159 
source, in a clinical scenario consistent with bacteraemia, defined VRE bacteraemia in 160 
one study (21). The presence of one or more blood cultures positive for VRE (without 161 
further clarifications) was used in three studies (5, 22, 24). In the remaining two 162 
studies an explicit definition of VRE BSI was not provided (23, 26).  163 
Statistically significant differences in potential confounders between groups of 164 
patients treated with daptomycin or linezolid are listed in Table S3 in the 165 
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supplemental material. Adjustments for potential confounders by the authors were 166 
performed using multivariable logistic regression analysis in six studies (4, 20-22, 24, 167 
27).  168 
The median daily daptomycin dose was 6mg/kg in six studies (5, 20-22, 26, 27), 169 
5.5mg/kg in one study (25), and dose was not reported in three studies (4, 23, 24). The 170 
median duration of treatment ranged between 13 and 15 days in the daptomycin group 171 
and between 11 and 15 days in the linezolid group, respectively (20-22, 27). 172 
Combination with aminoglycosides was reported in two studies (21, 27). Patients 173 
simultaneously treated with more than one anti-VRE agent were excluded in two 174 
studies (5, 20) (see Table S4 in the supplemental material). 175 
Prior vancomycin use was reported in two studies (21, 27), being significantly 176 
different across groups in one of them (21). Four studies reported inclusion of patients 177 
with endocarditis (5, 20, 21, 27). Outcomes of these patients were reported separately 178 
from non-endocarditis bacteraemia in one study only (27). Patients were switched 179 
from linezolid to daptomycin during treatment of bacteraemia in two studies (due to 180 
failure, intolerance or clinical preference (21), and resistance or intolerance (24) 181 
respectively) and one patient has switched from daptomycin to linezolid due to 182 
adverse events (25). Linezolid susceptibility was tested in three studies (5, 20, 25) and 183 
daptomycin susceptibility in two studies (5, 20). 184 
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Meta-analysis 185 
Thirty-day all-cause mortality 186 
All-cause mortality at 30 days (our pre-specified primary endpoint) was significantly 187 
increased in patients treated with daptomycin as compared to those treated with 188 
linezolid (OR: 1.61, 95% CI: 1.08 to 2.40; fixed effects model; heterogeneity: p=0.42) 189 
(Figure 1A). No publication bias was detected (Egger’s test: p=0.84). Four studies 190 
offered data for this outcome (4, 5, 22, 25).  191 
In two studies odds ratios were adjusted for potential confounders in multivariate 192 
logistic regression models (4, 22). When these were combined, still a statistically 193 
significant increase in mortality rate was present in patients of the daptomycin group 194 
as compared to those in the linezolid group (adjusted OR: 2.56, 95% CI: 1.29 to 5.08; 195 
fixed effects model; heterogeneity: p=0.36) (Figure 1B). 196 
Infection-related mortality 197 
Infection-related mortality was significantly higher in patients who received 198 
daptomycin compared to linezolid (OR: 3.61, 95% CI: 1.42 to 9.20; fixed effects 199 
model; heterogeneity: p=0.49) (Figure 2A). Adjusted odds ratios for infection-related 200 
mortality were not available. 201 
In-hospital mortality  202 
In-hospital mortality rate was significantly higher with daptomycin compared to 203 
linezolid (OR: 1.83, 95% CI: 1.05 to 3.20; fixed effects model; heterogeneity: p=0.69) 204 
(Figure 2B). Two studies estimated adjusted odds ratios for in-hospital mortality after 205 
controlling for potential confounders in multivariate logistic regression models (21, 206 
27). When these data were combined, higher mortality with daptomycin was 207 
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observed, however the difference did not reach statistical significance (OR: 1.65, 95% 208 
CI: 0.56 to 4.90; fixed effects model; heterogeneity: p=0.95). 209 
In the study by Crank et al. 21 patients were switched to daptomycin after linezolid 210 
failure, intolerance or other reason as determined by the treating physicians (21). The 211 
odds ratio for mortality in this case was calculated after excluding these 21 patients, 212 
while the adjusted odds ratios provided by the authors of this study were statistically 213 
controlled for prior linezolid use. 214 
Overall mortality 215 
Overall mortality rate, as defined for the purposes of this meta-analysis, was 216 
significantly increased in patients treated with daptomycin compared to linezolid for 217 
VRE bacteraemia (OR: 1.41, 95% CI: 1.06 to 1.89; fixed effects model; 218 
heterogeneity: p=0.50). No publication bias was detected (Egger’s test: p=0.58) 219 
(Figure 3A).  220 
In the study by Furuya et al. a significant proportion of patients were switched to 221 
daptomycin following linezolid failure or intolerance (24). Since this could have 222 
potentially resulted in bias, we performed a sensitivity analysis excluding this study, 223 
which did not substantially alter the findings (OR: 1.48, 95% CI: 1.09 to 2.00; fixed 224 
effects model, heterogeneity: p=0.54).  225 
Five studies provided adjusted odds ratios after controlling for potential confounders 226 
(4, 20-22, 27). When these data were pooled, overall mortality was still significantly 227 
increased in the daptomycin group as compared to the linezolid group (OR: 1.99, 95% 228 
CI: 1.19 to 3.32; fixed effects model; heterogeneity: p=0.71) (Figure 3B).  229 
Clinical cure 230 
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A significant difference in clinical cure rate was not detected in patients treated with 231 
daptomycin compared to linezolid (OR: 1.04 95% CI: 0.63 to 1.72; fixed effects 232 
model; heterogeneity: p=0.12). Three studies provided data for this outcome (5, 20, 233 
23).  234 
Microbiological cure 235 
Microbiological cure rates did not significantly differ between the two groups (OR: 236 
0.75, 95% CI: 0.41 to 1.39; fixed effects model; heterogeneity: p =0.76) (Figure 4A). 237 
Six studies offered data on this outcome (5, 20, 22, 23, 26, 27).  238 
Recurrence of VRE bacteraemia 239 
There was a trend towards higher relapse rates among patients treated with 240 
daptomycin compared to linezolid, the difference marginally failing to reach 241 
statistical significance (OR: 2.51, 95% CI: 0.94 to 6.72; fixed effects model; 242 
heterogeneity: p=0.42) (Figure 4B). Data for this outcome were provided by four 243 
studies (5, 20, 26, 27).  244 
Adverse events 245 
Notwithstanding the study by Kraft et al. which reported a significant difference in 246 
increased liver function tests among patients treated with daptomycin (25), no 247 
significant differences in adverse event rates between the two groups were detected, 248 





The present systematic review and meta-analysis summarizes the available data 253 
regarding the efficacy of linezolid versus daptomycin for the treatment of VRE 254 
bacteremia. To the best of our knowledge this the first study that attempts to critically 255 
appraise the existing evidence on this controversial issue. Based on the meta-analysis 256 
results, 30-day all-cause mortality was significantly higher among patients with VRE 257 
bacteraemia who were treated with daptomycin compared to those treated with 258 
linezolid. Notably also, the in-hospital mortality and the infection-related mortality 259 
rates were also increased in the daptomycin group as compared to linezolid. These 260 
findings were not materially altered in the sensitivity analyses (performed by pooling 261 
the adjusted odds ratios for mortality that were provided by the authors of individual 262 
studies). Administration of both drugs was relatively safe in those high-risk patient 263 
cohorts and frequency of adverse events did not seem to differ between the two 264 
treatment options. 265 
An important strength of meta-analysis is its inherent ability to increase the statistical 266 
power of individual studies. Notably, most of the studies included in this analysis 267 
showed a trend towards increased mortality rates among patients treated with 268 
daptomycin. With the exception, however, of one study (22), the difference from 269 
linezolid did not reach statistical significance. When the results of individual studies 270 
were combined, a significant increase in all mortality outcomes in the daptomycin 271 
group surfaced, coupled with negligible (I
2
= 0%) heterogeneity across studies. We 272 
acknowledge, however, that despite the absence of statistical heterogeneity, 273 
significant clinical heterogeneity was present across the studies analyzed (i.e. in terms 274 
of patients included, other antibiotics used, doses, etc., summarized in Tables S2-S4). 275 
For this reason, the results of the studies were also combined with the use of a random 276 
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effects model, and the pooled estimates for all mortality outcomes remained unaltered 277 
(data not shown). Hence, the results obtained in this meta-analysis are stable and, 278 
thus, they seem to accurately reflect the underlying effect present in the available 279 
comparative studies. 280 
In order to further increase the statistical power of this meta-analysis, a composite 281 
outcome of overall mortality rate was calculated. This outcome combined data on 282 
mortality from individual studies, whether this was expressed as 30-day all-cause 283 
mortality (n=4) (4, 5, 22, 25), in-hospital mortality (n=2) (21, 27), infection-related 284 
mortality (n=1) (23), mortality at the end of therapy (n=1) (24), mortality at seven 285 
days after the end of therapy (n=1) (20), or overall mortality (n=1) (26). The pooled 286 
overall mortality rate confirmed the findings of primary analysis. 287 
Certain limitations apply for the interpretation of our results. All available studies 288 
were retrospective and observational. The possibility of significant confounders, 289 
therefore, exists (e.g. selection bias: patients with worst prognosis being treated with 290 
daptomycin; patients able to swallow being treated with linezolid, etc). A proportion 291 
of patients treated with either agent were later changed to the other (usually due to 292 
failure), had previously received another antibiotic (typically vancomycin) or had 293 
additional organisms recovered in blood cultures. Characteristics like the presence of 294 
endocarditis (5, 20, 21, 27); source of any secondary bacteraemias (20, 21) (including 295 
the –rare- possibility of enterococcal pneumonias, where daptomycin would not be 296 
indicated); treating physicians and ID consultations (4); daptomycin dosing (5, 20-22, 297 
25-27); and combination therapies were not available for all patients (21, 27). 298 
Although such biases cannot be eliminated outside the context of a randomized 299 
prospective trial, we note that results from adjustment that took into account known 300 
confounders (listed in Table S3) were all in agreement with those of the primary 301 
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analysis. We note in relevance that pooling such patients (i.e  with and without 302 
endocarditis; with and without additional therapies, etc) risks in itself introducing 303 
bias. Even so, consistent results in favour of linezolid were obtained, when authors of 304 
individual studies adjusted for known confounders (4, 20-22, 27). Notably, similar 305 
characteristics between the two patient groups were recorded in most studies; in fact 306 
factors associated with unfavorable prognosis were over-represented among the 307 
linezolid patient group in some studies (i.e. patients being older (4, 5, 27), in ICU 308 
(20), or with higher APACHE scores (27). On the other hand, whether daptomycin or 309 
linezolid is advantageous in specific patient populations (e.g. haemodialysis, 310 
transplant recipients, etc) could not be evaluated in the present study, due to the 311 
limited number of data available.  312 
A potential explanation for the observed inferior outcomes of patients treated for VRE 313 
bacteremia with a bactericidal agent (daptomycin) than those treated with a 314 
bacteriostatic (linezolid) should perhaps be sought in the context of recent reports on 315 
daptomycin failures during treatment of enterococcal infections and emergence of 316 
resistance especially among VRE strains (28-30). In regards with this, we note the 317 
higher (although marginally failing statistical significance) relapse rates of VRE 318 
bacteraemia following daptomycin treatment compared to linezolid in our analysis 319 
(Figure 4B). In contrast with mortality and tendency of relapses, clinical and 320 
microbiological cure rates did not differ between the two agents. Given that neither 321 
for mortality causes, nor for clinical/microbiological cure data was available for all 322 
studies, a definite conclusion on any relation between those outcomes cannot be 323 
drawn with certainty.  324 
Optimal daptomycin dosing for treatment of severe infections remains a challenge, as 325 
higher doses have been proposed (29, 31) and recently supported from in vitro data 326 
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for VRE (32). Inferences regarding the optimal dose of daptomycin for treating VRE 327 
bacteraemia could not be made from this review, since six out of seven studies used a 328 
median dose of 6mg/kg (5, 20-22, 26, 27), while one study used a median dose of 329 
5.5mg/kg (25). It is possible that some of the suboptimal outcomes were associated 330 
with daptomycin underdosing (i.e < 6mg/kg). Whether even higher, off-label, 331 
daptomycin doses would increase efficacy in the treatment of VRE bacteraemia, 332 
without increasing toxicity, remains also to be explored. Similarly, the effect of 333 
proposed strategies of combination treatment with daptomycin and ampicillin (30) or 334 
rifampicin (33) could not be adequately assessed from these data.  335 
Based on the evidence summarized herein, daptomycin may be associated with worse 336 
outcomes in patients treated for VRE bacteraemia compared to linezolid. Given, 337 
however, the methodologic limitations of the existing studies, a properly designed 338 
randomized controlled multicenter trial to evaluate therapeutic options for VRE 339 
bacteraemia is required, albeit this would be a challenging task.  340 
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